NASDAQ$VERA
Vera Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported business highlights and financial results for the third quarter ended September 30, 2023.
Vera Therapeutics reported a net loss of $20.1 million for the third quarter ended September 30, 2023. The company's cash, cash equivalents, and marketable securities totaled $159.9 million as of September 30, 2023. The company expects these to fund operations to early 2026.
- Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgAN
- Announced analysis of Phase 2b ORIGIN study showing resolution of hematuria in the majority of patients, at the American Society of Nephrology Kidney Week 2023
- Presented data at ASN Kidney Week 2023 showing patients on atacicept 150 mg achieved durable and significant Gd-IgA1 reduction over 36 weeks where regardless of baseline quartile, 82% of patients (n=27/33) achieved reduction to the lowest risk quartile.
- Strong balance sheet expected to fund operations to early 2026
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$934K
Forward guidance
Vera Therapeutics anticipates several milestones including presenting OLE data from the ORIGIN Phase 2b clinical trial in the first quarter of 2024, full enrollment in the Phase 3 study in the second half of 2024, and topline data from the pivotal ORIGIN 3 trial in the first half of 2025.
Tailwinds
- OLE data from ORIGIN Phase 2b clinical trial to be presented in the first quarter of 2024
- Phase 3 full enrollment estimated in the second half of 2024
- Topline data from the pivotal ORIGIN 3 trial expected to be presented in the first half of 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro